

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 May 2026

A study to evaluate the effect of Montelukast tablets on respiratory complications in patients with multiple trauma suffering from lung injury; a double blind randomized clinical trial

Protocol summary

Study aim

To determine the effect of Montelukast tablets on respiratory complications detected in patients with multiple trauma suffering from lung injury

Design

Phase 2 clinical trial with control group, with parallel, double blind and randomized groups (En block randomization - Individual Random Unit- Using a sealed envelope). One group receives medication (Montelukast) and the other Group receives placebo. The sample size is 60 patients in both groups.

Settings and conduct

The study site is Shahid Rajaei trauma hospital of Shiraz. Patients who have inclusion criteria, will be randomly divided into either drug or placebo groups. Standard care will be provided for patients and they will follow for 7 days. Computed tomography is performed on the day of entry and on the seventh day and results are recorded. The study is blinded to participants, carers, evaluators, and analyzers.

Participants/Inclusion and exclusion criteria

Inclusion Criteria: Patients with blunt multiple trauma and at least 3 fractured ribs, Patients with blunt multiple trauma and lung contusion detected in CT scan performed on arrival, Exclusion Criteria: Patients younger than 16 years, Patients with penetrating trauma, Patients with history of cardiopulmonary disease, Patients with history of hypersensitivity to Montelukast, Patients who will not sign the informed written consent

Intervention groups

Intervention group: Airokast® (Montelukast -as sodium-Abidi company) 10 mg Orally, Once daily for 7 days
Control group: Placebo pills (Produced in the Faculty of Pharmacy, Shiraz University of Medical Sciences) the same as Monteleukast tablets, Orally, Once daily for 7 days

Main outcome variables

CT scan findings about volume and location of lung contusion; Pulmonary complication like acute lung injury, acute respiratory distress syndrome and pneumonia

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190719044270N1**

Registration date: **2019-11-08, 1398/08/17**

Registration timing: **registered_while_recruiting**

Last update: **2019-11-08, 1398/08/17**

Update count: **0**

Registration date

2019-11-08, 1398/08/17

Registrant information

Name

Ali Taheri Akerdi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3625 4206

Email address

ata110iran@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-09-23, 1398/07/01

Expected recruitment end date

2020-03-19, 1398/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A study to evaluate the effect of Montelukast tablets on respiratory complications in patients with multiple trauma suffering from lung injury; a double blind randomized clinical trial

Public title

The effect of Montelukast on respiratory complications detected in patients with multiple trauma and lung injury

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

Patients with blunt multiple trauma and at least 3 fractured ribs Patients with blunt multiple trauma and lung contusion detected in CT scan performed on arrival

Exclusion criteria:

Patients younger than 16 years Patients with penetrating trauma Patients with history of cardiopulmonary disease Patients with history of hypersensitivity to Montelukast Patients who will not sign the informed written consent

Age

From **16 years** old

Gender

Both

Phase

2

Groups that have been masked

- Participant
- Care provider
- Outcome assessor
- Data analyser

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

block randomization - Individual Random Unit- Using a sealed envelope. We Use "Random allocation Software" to allocate 60 patients into Two Groups randomly by using blocks size of 4. These random numbers and drugs (placebo or true medication) are placed in envelopes and then, as each patient arrives, an envelope is opened and treatment is applied to each individual. Obviously, the drug in the envelope is also not detectable for staffs in terms of being a placebo or true medication.

Blinding (investigator's opinion)

Double blinded

Blinding description

The placebo tablets will be provided in the same color, shape, size, and weight as the Monteleukast tablets .They will be packaged in the same packages, too. A unique number will be written on each package (Monteleukast or placebo). This number and its corresponding contents (Monteleukast or placebo) will be recorded by the researcher. The numbered packages will

be provided to the patient's nurse. The nurses will be asked to record the numbers on the package in the relevant form after being used by the patient and obtaining the medical, clinical and laboratory data. Consequently, the nurses, staffs, and patients will only encountered the numbers on the packages but not their content. After removing the participant name from the CT images, a unique number will be lithographed on each image. As a result, the radiologist will be unaware of the patient's name and the therapy. The Radiologist will record the number after reporting the images on the report form. Only the researcher will have access to the corresponding names and numbers. After the therapy course a new CT scan will be done. The patients names will be removed in the first step .A new number, independent of the numbers written on the pre-treatment images, will be lithographed on the new images. Consequently, the radiologist will be blind to therapy effect in the follow-up images. Finally, the data will be entered in a statistical analysis software. The case and control groups will be labeled as group A and B. Afterward, the statistical information will be sent to the statistical specialist, who is blind to case and control group.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee affiliated to Baqiyatallah University of Medical Sciences

Street address

Bagheit_Allah Medical School, South Sheykh Bahae St, Molasadra St, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1435916471

Approval date

2019-07-08, 1398/04/17

Ethics committee reference number

IR.BMSU.REC.1398.112

Health conditions studied**1****Description of health condition studied**

Contusion of lung

ICD-10 code

S27.32

ICD-10 code description

Contusion of lung

2**Description of health condition studied**

Multiple fractures of ribs

ICD-10 code

S22.4

ICD-10 code description

Multiple fractures of ribs

3**Description of health condition studied**

Acute respiratory distress syndrome

ICD-10 code

J80

ICD-10 code description

Acute respiratory distress syndrome

4**Description of health condition studied**

Pneumonia

ICD-10 code

B95.3

ICD-10 code description

Streptococcus pneumoniae as the cause of diseases classified elsewhere

5**Description of health condition studied**

Pulmonary embolism

ICD-10 code

I26

ICD-10 code description

Pulmonary embolism

Primary outcomes**1****Description**

Lung contusion

Timepoint

on day 0 and 7

Method of measurement

Chest CT-scan

2**Description**

Acute Lung Injury

Timepoint

on day 7

Method of measurement

Chest CT-scan

3**Description**

Acute Respiratory Distress Syndrome

Timepoint

on day 7

Method of measurement

Chest CT-scan

4**Description**

Pulmonary Emboli

Timepoint

on day 7

Method of measurement

Chest CT angiography

5**Description**

Pneumonia

Timepoint

on day 7

Method of measurement

Chest CTscan

Secondary outcomes**1****Description**

C reactive Protein

Timepoint

day 0 and 3

Method of measurement

Serum agglutination test

2**Description**

Procalcitonin

Timepoint

day 3

Method of measurement

Blood level of procalcitonin

3**Description**

Length of ICU stay

Timepoint

Discharge from ICU

Method of measurement

counting ICU admission days

4**Description**

Days underwent ventilator assisted respiration

Timepoint

on discharge

Method of measurement

counting the days underwent ventilator assisted respiration

Intervention groups

1

Description

Intervention group: Airokast® (Montelukast -as sodium-Abidi company) 10 mg Orally, Once daily for 7 days

Category

Prevention

2

Description

Control group: Placebo pills (Produced in the Faculty of Pharmacy, Shiraz University of Medical Sciences) like real drug, Orally, Once daily for 7 days

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Shiraz Rajaei Hospital

Full name of responsible person

Ali Taheri Akerdi

Street address

Trauma Research Center, Rajaei Hospital, Chamran Avenue, Shiraz

City

Shiraz

Province

Fars

Postal code

7194815711

Phone

+98 71 3625 4206

Email

ata110iran@gmail.com

Web page address

<https://rajaeehosp.sums.ac.ir>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Bagheiat-allah University of Medical Sciences

Full name of responsible person

Soleyman Heydari

Street address

Bagheit_Allah Medical School, South Sheykh Bahaei St, Molasadra St, Tehran

City

Tehran

Province

Tehran

Postal code

1435916471

Phone

+98 21 8804 0060

Email

heydari.dr@gmail.com

Web page address

<https://www.bmsu.ac.ir>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Bagheiat-allah University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Bagheiat-allah University of Medical Sciences

Full name of responsible person

Ali Taheri Akerdi

Position

General Surgeon - Researcher

Latest degree

Specialist

Other areas of specialty/work

General Surgery

Street address

Shahid Rajaei Hospital, Chamran Avenue, Shiraz, Iran

City

Shiraz

Province

Fars

Postal code

7194815711

Phone

+98 71 3625 4206

Fax

Email

ata110iran@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Bagheiat-allah University of Medical Sciences

Full name of responsible person

Ali Taheri Akerdi

Position

General Surgeon - Researcher

Latest degree

Specialist

Other areas of specialty/work

General Surgery

Street address

Shahid Rajaei Hospital, Chamran Avenue, Shiraz, Iran

City

Shiraz

Province

Fars

Postal code

7194815711

Phone

+98 71 3625 4206

Fax

Email

ata110iran@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Bagheiat-allah University of Medical Sciences

Full name of responsible person

Ali Taheri Akerdi

Position

General Surgeon - Researcher

Latest degree

Specialist

Other areas of specialty/work

General Surgery

Street address

Shahid Rajaei Hospital, Chamran Avenue

City

Shiraz

Province

Fars

Postal code

7194815711

Phone

+98 71 3625 4206

Fax

Email

ata110iran@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

The baseline, clinical, and outcome measures databases would be available in SPSS format after publication of the study

When the data will become available and for how long

The data will be available immediately after publication of the study

To whom data/document is available

The data would be available to the readers of published article through the journals website

Under which criteria data/document could be used

There is not limitation for accessing the study data after publication

From where data/document is obtainable

The database would be available as an appendix to the published article

What processes are involved for a request to access data/document

The database would be available as an appendix to the published article. The availability would be according to the publishers policy

Comments